The Research Frontier: Open Questions and the Analytical Bottleneck

The combinatorial argument, and its honest limits contested

Count the axes. Eleven structural types. Eight documented side-chain lengths. For the THC-type skeleton alone, several viable alkene positions plus the iso-ring-closure family. Two stereocentres giving four configurations where the skeleton is chiral. An acid and a neutral form for each. Multiply and the count of chemically reasonable structures runs into the thousands. That is the arithmetic the operator source uses and it is sound as an order-of-magnitude statement. Two honesty notes belong with it. Not every cell in that grid is chemically reasonable or biosynthetically accessible — some combinations are strained, some are unstable, and the plant does not make them all — so the product is an upper bound rather than a census. And a very large number of possible structures is not by itself interesting. What makes the space worth mapping is that the sparsely populated regions include compounds whose relatives are pharmacologically distinctive: the propyl homologue reverses sign at CB1, the heptyl homologue binds thirty times more tightly, the acids have targets of their own. The gaps are where the surprises have been.

Contested — caveat. The "thousands of possible cannabinoids" figure is an extrapolation from a combinatorial count, not an inventory of characterised or even detected compounds. It is an upper bound: some combinations are chemically unreasonable and most have never been observed. Use it as an argument about the scale of the unexplored space, not as a claim about existing compounds.

Sources: Radwan MM 2021 · Hanuš LO 2016 · Thomas A 2005 · Citti C 2019 · Van Kush Family Research Institute 2026*

The phorolic acid series: implied by the pathway, largely uncharacterised contested

If the heptyl side chain reaches CBGPA, then the three oxidocyclases should route it exactly as they route CBGA, and the passive degradation chemistry should act on the products exactly as it acts on the pentyl series. That predicts a full parallel heptyl family in acid form — the CBG, CBC, CBE, CBL and CBN counterparts — of which almost nothing is characterised. This is a clean set of research questions: does each predicted acid occur in plant material at detectable level, what are the chromatographic and spectroscopic properties that would let a laboratory recognise it, and what does the corresponding neutral form do at the cannabinoid receptors. The operator source lists six specific phorolic acids as targets. That list is a reasonable prediction from the pathway rather than a report of detected compounds, and it should be treated as a hypothesis set to test rather than an inventory.

Contested — caveat. The specific list of phorolic acids given in the operator source (CBGPA, CBCPA, CBEPA, CBRPA, CBLPA, CBNPA) could not be verified as reported, detected compounds in the primary literature in this pass. Treat these as pathway-predicted targets, not as identified phytocannabinoids. CBGP and CBCP are described in the literature as putative identifications.

Sources: Citti C 2019 · Hanuš LO 2016 · Radwan MM 2021 · Van Kush Family Research Institute 2026*

The butyl and hexyl homologues: detected, then dropped in vitro

The C4 and C6 series are the most tractable frontier because they are already past the hardest step. Linciano and colleagues isolated Δ9-THCB and CBDB from the Italian FM2 medicinal variety and reported CB1 and CB2 affinities for THCB — Ki 15 nM at CB1 and 51 nM at CB2, which the authors described as comparable to Δ9-THC — and in a second paper identified the hexyl homologue cannabidihexol with antinociceptive activity in mice. After those initial reports the pharmacological work largely stopped. Functional characterisation across signalling pathways, metabolism, pharmacokinetics, and the corresponding acids are all open. The 2026 homologue study begins to fill this in on synthetic material and for the first time reports pathway bias across C3 to C8, which is the shape the rest of this work should take.

Sources: Linciano P 2020 · Linciano P 2020 · Durydivka O 2026

The rare structural types are essentially blank

Four types — CBE, CBL, CBT and CBND — have almost no receptor pharmacology in the literature at all, and their homologue series are blank beyond the occasional propyl member. The reasons are practical rather than scientific: they occur at low abundance, several of them are degradation products rather than plant products, reference standards are scarce or nonexistent, and nobody has had a commercial reason to look. That is exactly the profile of a neglected research area rather than a closed one. Several specific questions are worth naming. What does the strained cyclobutane of the CBL type do to receptor interaction, given that it holds the molecule in a geometry nothing else in the family adopts. Is the CBT type, whose extra hydroxylation changes polarity and viscosity, pharmacologically inert or merely unexamined. Does CBND behave to CBD as CBN does to THC — a degradation product with reduced activity — or does the open skeleton behave differently on aromatisation.

Sources: Hanuš LO 2016 · Radwan MM 2021 · ElSohly MA 2005

The acidic cannabinoids as agents in their own right animal

The acids are not merely precursors, and the evidence that they are not is reasonably strong for two of them. Cannabidiolic acid enhances activation of the 5-HT1A receptor and, in the standard animal models of emesis and nausea-induced behaviour, is roughly a hundred times more potent than cannabidiol — an effect abolished by a selective 5-HT1A antagonist, which is what makes it a mechanism rather than an observation. Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity in cell and animal models, with the effects blocked by PPARγ antagonists. Both findings point the same direction: this is a pharmacology with its own targets rather than a weaker version of the neutral cannabinoids’ pharmacology, and it is systematically under-studied relative to how much of the material in a living plant is in acid form. The open questions are the obvious ones. What do the other acids do. What do the acids of the homologous series do. How much of the reported activity of a whole-plant preparation is attributable to the acid fraction that the neutral-cannabinoid literature has never measured.

Sources: Bolognini D 2013 · Nadal X 2017 · Filer CN 2022

The bottleneck is analytical, and this is the honest framing of the whole frontier

Every question above runs through one constraint. A compound cannot be identified unless something establishes which peak it is, and for isomers that share an exact mass the only thing that establishes it is retention time matched against an authentic reference standard. A compound cannot be quantified without a standard either, because quantitation needs a response factor. So a compound for which no certified reference standard exists is, for practical purposes, invisible: it cannot appear correctly on a certificate of analysis, it cannot be dosed, its stability cannot be tracked, its pharmacology cannot be tied to a defined substance, and its presence in a product cannot be confirmed or excluded. This is why reference-standard development is the rate-limiting step for the entire field rather than a procurement inconvenience. It is also the reason the frontier is genuinely open: the limit on what can be known about these compounds is not conceptual, it is the availability of characterised, certified material to calibrate against — and that is a tractable problem that an institute can work on directly.

Sources: Caprari C 2024 · Kiselak TD 2020 · Bloemendal VRLJ 2020

Research questions a hemp-sciences institute could actually take up

Each of these is a research programme with a publishable output, and each is framed as a question about characterisation, measurement or mechanism. None is framed as a production opportunity, because the gaps described on this page are gaps in knowledge and the useful response to them is knowledge.

Sources: Durydivka O 2026 · Caprari C 2024 · de Meijer EPM 2003 · Lindholst C 2010 · Jaidee W 2022 · Kiselak TD 2020 · Bolognini D 2013 · Nadal X 2017 · Linciano P 2020 · Linciano P 2020

What the field has, versus what it could have

To close with the numbers in one place: on the order of 120 to 150 phytocannabinoids have been isolated and structurally characterised, depending on which review is counted and how strictly identifications are judged. Of those, a few dozen have any receptor pharmacology, and a considerably smaller number have been profiled across more than one functional endpoint. Certified reference standards exist for a still smaller subset, which is the set that any laboratory anywhere can actually report on a certificate. Against a possible space in the thousands, that is a field at the beginning rather than the middle of its work — and the beginning of the work is analytical.

Sources: Radwan MM 2021 · Hanuš LO 2016 · ElSohly MA 2005 · Caprari C 2024